Year |
Milestones |
2009 |
Frost & Sullivan Award for Global Excellence in Diabetes Research
3rd generation handheld prototype completed
Epinex CEO Asad Zaidi presented with SABAN award for entrepreneurial success
Epinex prepares detailed marketing and media plan for the G1A™ test
Epinex invited to New York Academy of Sciences conference on diabetes
|
2008 |
Second Private Placement launched for $15 million
Corporate Information Series published:
Understanding Diabetes
Glycated Albumin and Diabetes Monitoring
Diabetes in The Middle East
Review article published in the peer-reviewed diabetes research journal The Journal of Diabetes of Science and Technology
Peptide and custom antibody projects initiated to produce proprietary analytes for the G1A™ test
Desktop/doctor's office reader prototype and software design completed
|
2007 |
Oakridge Poster Presentation of posters at major clinical chemistry meetings: AACC Oakridge Conference in Oakland, CA, 2007 Annual AACC Meeting in San Diego, CA and IFCC EuroMedlab Conference in Amsterdam, The Netherlands
First Action taken on US and European patent applications
First Private Placement Memorandum offering for $5 million successfully completed
|
2006 |
G1A™ Test Strip Prototype: Initial prototype single channel test strips for total and glycated albumin designed and tested
US and European patent applications published
Glycated Albumin abstract and review published
G1A™ Handheld Prototype: Single channel handheld reader completed
2nd Open House and live webcast for investors held
|
2005 |
WIPO application published
G1A™ test feasibility survey sent to 3500 endocrinologist worldwide
1st Open House: Hosted an open house for Company investors and local business contacts
Monograph published: "Towards a New Glycation Index", background information about glycemic control and glycated albumin
GA Test signal amplified
|
2004 |
Advisory Board assembled
European, Canadian, Japanese provisional patents filed
|
2003 |
First Private Placement Memorandum launched for $5 million
Preliminary background research on the Glycated Albumin molecule was conducted to evaluate feasibility
Provisional US patent filed
|
2002 |
Epinex Diagnostics incorporated as California C-corp |
